Official company source

Retatrutide demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes.

Eli Lilly and Company. Retatrutide demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. News release, 2026-03-19.

Eli Lilly and CompanyPublished Mar 19, 2026Accessed Jul 12, 2026

Open original source

Registry record

Source metadata

Publisher: Eli Lilly and Company
Source type: Official company source
Registry ID: research-reta-10
Source code: RETA-10

Source usage

Linked from 1 page

Compound

Retatrutide

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.